Inhibrx Biosciences (INBX) Equity Ratio (2023 - 2025)
Historic Equity Ratio for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to 0.21.
- Inhibrx Biosciences' Equity Ratio fell 7411.98% to 0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.21, marking a year-over-year decrease of 7411.98%. This contributed to the annual value of 0.74 for FY2024, which is 42301.71% up from last year.
- As of Q3 2025, Inhibrx Biosciences' Equity Ratio stood at 0.21, which was down 7411.98% from 0.32 recorded in Q2 2025.
- Inhibrx Biosciences' Equity Ratio's 5-year high stood at 0.85 during Q2 2024, with a 5-year trough of 0.14 in Q4 2023.
- Over the past 3 years, Inhibrx Biosciences' median Equity Ratio value was 0.39 (recorded in 2025), while the average stood at 0.49.
- In the last 5 years, Inhibrx Biosciences' Equity Ratio skyrocketed by 42301.71% in 2024 and then plummeted by 7411.98% in 2025.
- Inhibrx Biosciences' Equity Ratio (Quarter) stood at 0.14 in 2023, then skyrocketed by 423.02% to 0.74 in 2024, then plummeted by 71.92% to 0.21 in 2025.
- Its last three reported values are 0.21 in Q3 2025, 0.32 for Q2 2025, and 0.39 during Q1 2025.